Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane and ubiquitin-like domain containing 1 (TMUB1)
- Target
- TMUB1
- Molecular classification
- Ubiquitin-like domain-containing protein, Transmembrane protein, Other (not a classical GPCR, ion channel, enzyme, transporter, or transcription factor)
01
Overview
Transmembrane and ubiquitin-like domain containing 1 (TMUB1) is a human protein-coding gene that encodes a transmembrane protein featuring a ubiquitin-like (UBL) domain[3][4]. TMUB1 is expressed in the central nervous system (notably in thalamus, cortex, and cerebellum), with roles in regulating AMPA receptor trafficking, wakefulness, and locomotor activity[1]. It binds to CAMLG and participates in membrane trafficking[1]. TMUB1 is involved in protein ubiquitination and degradation pathways, influences cell proliferation, centrosome assembly, and negatively regulates liver regeneration[3]. Overexpression is linked to poor prognosis in various cancers, particularly glioma, making it both a biomarker and a potential therapeutic target[2][6].
- Other names
- C7orf21HOPSDendritic cell-derived ubiquitin-like proteinDULP
02
Mechanism of action
No drugs with defined mechanisms of action targeting TMUB1. Knockdown or genetic inhibition reduces tumor growth in experimental models, indicating negative regulation of cell proliferation as a potential mechanism[2].
03
Biological functions
Regulation of AMPA-type glutamate receptor recycling to the cell surfaceModulation of proteasomal degradation and ubiquitinationRegulation of locomotor activity and wakefulnessCentrosome assemblyRegulation of cell proliferationRegulation of cell cycleNegative regulation of liver regeneration
04
Disease associations
Cancer (notably glioma and colon cancer)May be involved in neurobiology (linked to wakefulness and brain development in animal models)
05
Safety considerations
There are no widely reported therapeutic safety concerns associated with targeting TMUB1. Its diverse roles in cell cycle and the nervous system suggest potential on-target effects but no data confirming specific risks[1][2].
06
Biomarkers
TMUB1 expression is proposed as a prognostic biomarker in glioma: higher levels correlate with worse prognosis[2].
Beyond the preview
Go deeper on Transmembrane and ubiquitin-like domain containing 1 (TMUB1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transmembrane and ubiquitin-like domain containing 1 (TMUB1).